- Andelyn Biosciences and ENCell have signed a collaboration agreement to create a US–Asia-Pacific manufacturing corridor for gene therapies.
- The partnership aims to streamline development, contract manufacturing, and clinical supply through a dual-hemisphere production model.
Andelyn Biosciences and ENCell Co., Ltd. have entered into a strategic partnership to establish a manufacturing link between the United States and the Asia-Pacific region, aimed at supporting global gene therapy development and production. The agreement was announced on April 21, 2026, with operations spanning facilities in the US and South Korea.
The collaboration brings together two CDMOs with capabilities in cell and gene therapy manufacturing. It is designed to provide an integrated platform for development, GMP manufacturing, and clinical supply. By connecting regional manufacturing hubs, the companies aim to support clients conducting global clinical trials and planning international expansion.
Under the agreement, the companies will implement a “dual hemisphere” workflow. This model is intended to simplify cross-border operations by enabling local production for regional clinical trials. The approach is expected to reduce logistical and regulatory challenges while shortening lead times and supporting region-specific supply needs.
“Our partnership with ENCell is a powerful step forward in Andelyn’s mission to help bring life-saving therapies to patients worldwide. By joining forces with such a respected leader in South Korea, we are not just expanding our global footprint; we are leveraging our unique strengths to deliver a truly seamless international manufacturing network.”
Wade Macedone, CEO of Andelyn
The companies stated that the partnership will support the development and scalable production of gene therapies from early-stage programs through commercialization. The collaboration is positioned to expand access to advanced therapies by aligning manufacturing capabilities across key global regions.
